Table 1. Clinical characteristics of subjects for DNA chip and qRT-PCR analyses.
| DNA chip analysis | qRT-PCR analysis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | |||||||||
| HOMA-IR | HOMA-IR | HOMA-IR | HOMA-IR | |||||||||
| No. (male:female) | 6 (1:5) | 9 (6:3) | 5 (2:3) | 5 (4:1) | ||||||||
| Age (yr) | 58 | ± | 3 | 40 | ± | 3** | 55 | ± | 4 | 56 | ± | 5 |
| BMI (kg/m2) | 26.3 | ± | 1.9 | 26.1 | ± | 1.7 | 26.5 | ± | 1.6 | 29.4 | ± | 2.1 |
| FPG (mg/dL) | 99 | ± | 5 | 100 | ± | 8 | 96 | ± | 4 | 104 | ± | 3 |
| HbA1c (%) | 5.5 | ± | 0.2 | 5.6 | ± | 0.3 | 5.2 | ± | 0.3 | 6.9 | ± | 0.8 |
| HOMA-IR | 1.07 | ± | 0.11 | 3.77 | ± | 0.96* | 1.59 | ± | 0.19 | 3.35 | ± | 0.51* |
| AST (IU/L) | 20 | ± | 2 | 39 | ± | 6* | 32 | ± | 10 | 31 | ± | 6 |
| ALT (IU/L) | 18 | ± | 3 | 83 | ± | 24* | 40 | ± | 16 | 40 | ± | 9 |
| Total cholesterol (mg/dL) | 204 | ± | 20 | 198 | ± | 18 | 200 | ± | 22 | 166 | ± | 17 |
| Triglyceride (mg/dL) | 128 | ± | 28 | 136 | ± | 23 | 110 | ± | 24 | 139 | ± | 24 |
| Hepatic INHBE mRNA | 1.00 | ± | 0.15 | 1.66 | ± | 0.17* | 1.00 | ± | 0.08 | 2.10 | ± | 0.36* |
BMI: Body mass index, FPG: Fasting plasma glucose, Hb: Hemoglobin, HbA1c indicates glycosylated hemoglobin, AST: aspartate transaminase, ALT: alanine transaminase, HOMA-IR: Homeostasis model assessment of insulin resistance. Data are expressed as means ± SEM.
* P < 0.05
** P < 0.01, vs. low HOMA-IR group.